All Stories

  1. Preparation and Preliminary Evaluation of 68 Ga-Acridine: An Attempt to Study the Potential of Radiolabeled DNA Intercalator as a PET Radiotracer for Tumor Imaging
  2. 68Ga-labeled HBED-CC Variant of uPAR Targeting Peptide AE105 Compared with 68Ga-NODAGA-AE105
  3. 177 Lu-labeled cyclic Asn-Gly-Arg peptide tagged carbon nanospheres as tumor targeting radio-nanoprobes
  4. Effect of Number of Bifunctional Chelating Agents on the Pharmacokinetics and Immunoreactivity of 177Lu-labeled Rituximab: A Systemic Study
  5. An electrochemical approach for removal of radionuclidic contaminants of Eu from 153 Sm for effective use in metastatic bone pain palliation
  6. Preparation and comparative evaluation of 99m Tc-HYNIC-cNGR and 99m Tc-HYNIC-PEG2 -cNGR as tumor-targeting molecular imaging probes
  7. Comparative Evaluation of Using NOTA and DOTA Derivatives as Bifunctional Chelating Agents in the Preparation of 68Ga-Labeled Porphyrin: Impact on Pharmacokinetics and Tumor Uptake in a Mouse Model
  8. The potential of radiolabeled chemotherapeutics in tumor diagnosis: Preliminary investigations with 68 Ga-gemcitabine
  9. Clinically Relevant Radioactive Dose Formulation of 177 Lu-Labeled Cetuximab-Fab Fragment for Potential Use in Cancer Theranostics
  10. Studies towards elucidating the potential of 5,10,15,20-tetrakis(p-carboxy-methyleneoxyphenyl)porphyrin as a theranostic agent for applications in PET and PDT
  11. Comparative evaluation of 68 Ga-labeled NODAGA, DOTAGA, and HBED-CC-conjugated cNGR peptide chelates as tumor-targeted molecular imaging probes
  12. 68 Ga labeled Erlotinib: A novel PET probe for imaging EGFR over-expressing tumors
  13. Facile One-Pot Synthesis of Intrinsically Radiolabeled 64 Cu-Human Serum Albumin Nanocomposite for Cancer Targeting
  14. Preparation and Evaluation of 177Lu-Labeled Gemcitabine: An Effort Toward Developing Radiolabeled Chemotherapeutics for Targeted Therapy Applications
  15. 99m Tc-labeled NGR-chlorambucil conjugate, 99m Tc-HYNIC-CLB-c(NGR) for targeted chemotherapy and molecular imaging
  16. Development of 68Ga labeled human serum albumin for blood pool imaging: a comparison between two ligands
  17. In Vitro Evaluation of 188Re-HEDP: A Mechanistic View of Bone Pain Palliations
  18. Preclinical evaluation of 131 I-Bevacizumab – A prospective agent for radioimmunotherapy in VEGF expressing cancers
  19. ‘4+1’ Mixed Ligand Strategy for the Preparation of 99m Tc-Radiopharmaceuticals for Hypoxia Detecting Applications
  20. Radiochemical studies, pre-clinical investigation and preliminary clinical evaluation of 170 Tm-EDTMP prepared using in-house freeze-dried EDTMP kit
  21. Preliminary PET/CT Imaging with Somatostatin Analogs [68Ga]DOTAGA-TATE and [68Ga]DOTAGA-TOC
  22. Preparation of clinical-scale 177 Lu-Rituximab: Optimization of protocols for conjugation, radiolabeling, and freeze-dried kit formulation
  23. Radiosynthesis and evaluation of a 99mTc-folic acid radiotracer prepared using [99mTcN(PNP)]2+ metal fragment
  24. Biocompatibility and therapeutic evaluation of magnetic liposomes designed for self-controlled cancer hyperthermia and chemotherapy
  25. 68Ga-Chelation and comparative evaluation of N,N′-bis-[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N′-diacetic acid (HBED-CC) conjugated NGR and RGD peptides as tumor targeted molecular imaging probes
  26. 68 Ga labeled fatty acids for cardiac metabolic imaging: Influence of different bifunctional chelators
  27. Industrial-Scale Synthesis of Intrinsically Radiolabeled 64CuS Nanoparticles for Use in Positron Emission Tomography (PET) Imaging of Cancer
  28. Synthesis and evaluation of a 68Ga labeled folic acid derivative for targeting folate receptors
  29. Synthesis and comparativein vivoevaluation of99mTc(CO)3-labeled PEGylated and non-PEGylated cRGDfK peptide monomers
  30. Preparation and preliminary bioevaluation of 68Ga-oxine in lipiodol as a potential liver imaging agent
  31. Evaluation of 177Lu-CHX-A′′-DTPA-Bevacizumab as a radioimmunotherapy agent targeting VEGF expressing cancers
  32. Radiolabeling and Preliminary Evaluation of Ga-68 Labeled NODAGA-Ubiquicidin Fragments for Prospective Infection Imaging
  33. 90Y/177Lu-labelled Cetuximab immunoconjugates: radiochemistry optimization to clinical dose formulation
  34. Clinical translation of 177Lu-labeled PSMA-617: Initial experience in prostate cancer patients
  35. Palliative care of bone pain due to skeletal metastases: Exploring newer avenues using neutron activated 45 Ca
  36. Preparation and bioevaluation of [99mTcN]2+-labeled tetrameric complex of E-c(RGDfK)2 as a radiotracer for imaging αvβ3 integrins in tumors
  37. Mechanochemical synthesis of mesoporous tin oxide: a new generation nanosorbent for 68Ge/68Ga generator technology
  38. 177Lu-labeled carbon nanospheres: a new entry in the field of targeted radionanomedicine
  39. Modulation of in vivo distribution through chelator: Synthesis and evaluation of a 2-nitroimidazole–dipicolylamine–99mTc(CO)3 complex for detecting tumor hypoxia
  40. In-house preparation of macroaggregated albumin (MAA) for 68Ga labeling and its comparison with commercially available MAA
  41. 131 I-Nimotuzumab – A potential radioimmunotherapeutic agent in treatment of tumors expressing EGFR
  42. A systematic evaluation of the potential of PCTA-NCS ligand as a bifunctional chelating agent for design of 177Lu radiopharmaceuticals
  43. Preparation and evaluation of a single vial AMBA kit for 68Ga labeling with potential for imaging of GRP receptor-positive cancers
  44. Synthesis and bioevaluation of a 177Lu-labeled unsymmetrical cationic porphyrin derivative as a tumor targeting agent
  45. Neutral 99mTc(CO)3 complexes of “clicked” nitroimidazoles for the detection of tumor hypoxia
  46. Single vial kit formulation of DOTATATE for preparation of177Lu-labeled therapeutic radiopharmaceutical at hospital radiopharmacy
  47. A99mTc-Labeled Misonidazole Analogue: Step Toward a99mTc-Alternative to [18F]Fluromisonidazole for Detecting Tumor Hypoxia
  48. Single vial freeze-dried TRODAT-1 kit: Preparation and demonstration of clinical efficacy of [99mTc]TRODAT-1 in Indian scenario
  49. Formulation and evaluation of freeze-dried DOTMP kit for the preparation of clinical-scale 177Lu-DOTMP and 153Sm-DOTMP at the hospital radiopharmacy
  50. 64CuCl2 produced by direct neutron activation route as a cost-effective probe for cancer imaging: the journey has begun
  51. Formulation, Preclinical Evaluation, and Preliminary Clinical Investigation of an In-House Freeze-Dried EDTMP Kit Suitable for the Preparation of177Lu-EDTMP
  52. Single vial kit formulation for preparation of PET radiopharmaceutical: 68Ga-DOTA-TOC
  53. Radiosynthesis and Biological Evaluation of68Ga-Labeled Colchicine Conjugates
  54. Preparation of 99mTc carbonyl DTPA-bevacizumab and its bioevaluation in a melanoma model
  55. Radiosynthesis and Bioevaluation of [68Ga]-Labeled 5,10,15,20-Tetra(4-methylpyridyl)-porphyrin for Possible Application as a PET Radiotracer for Tumor Imaging
  56. Single vial formulation for theranostic radiopharmaceutical preparation
  57. Preparation and evaluation of three mucoadhesive dosage forms using 99mTc–Ofloxacin
  58. On the Application of Nafion Membrane for the Preparation of90Y Skin Patches, Quality Control, and Biological Evaluation for Treatment of Superficial Tumors
  59. Biphasic magnetic nanoparticles–nanovesicle hybrids for chemotherapy and self-controlled hyperthermia
  60. 99mTc carbonyl DTPA–Rituximab: Preparation and preliminary bioevaluation
  61. Development of Single Vial Kits for Preparation of 68Ga-Labelled Peptides for PET Imaging of Neuroendocrine Tumours
  62. Erbium-169 labeled hydroxyapatite particulates for use in radiation synovectomy of digital joints – a preliminary investigation
  63. Utilization of a novel electrochemical 90Sr/90Y generator for the preparation of 90Y-labeled RGD peptide dimer in clinically relevant dose
  64. Biocompatibility, biodistribution and efficacy of magnetic nanohydrogels in inhibiting growth of tumors in experimental mice models
  65. Development of Assamese Phonetic Engine: Some issues
  66. Radiolabeling, Stability Studies, and Pharmacokinetic Evaluation of Thulium-170-Labeled Acyclic and Cyclic Polyaminopolyphosphonic Acids
  67. Synthesis and Biological Evaluation of90Y-Labeled Porphyrin-DOTA Conjugate: A Potential Molecule for Targeted Tumor Therapy
  68. Preparation and evaluation of radioiodinated thermoresponsive polymer based on poly(N-isopropyl acrylamide) for radiotherapy
  69. The Practicality of Nanoceria-PAN-Based68Ge/68Ga Generator Toward Preparation of68Ga-Labeled Cyclic RGD Dimer as a Potential PET Radiotracer for Tumor Imaging
  70. Radiolabeling of Umbilical Cord-Derived Mesenchymal Stem Cells forIn VivoTracking
  71. Preparation of99mTc(CO)3-Carboxymethylthioethyl Iminodiacetic Acid and Evaluation as a Potential Renal Imaging Agent
  72. Effect of lipophilicity on biological properties of 109Pd-porphyrin complexes: a preliminary investigation
  73. Magnitude of radiation-induced DNA damage in peripheral blood leukocytes and its correlation with aggressiveness of thymic lymphoma in Swiss mice
  74. Studies on Efficacy of a Novel 177Lu-Labeled Porphyrin Derivative in Regression of Tumors in Mouse Model
  75. Synthesis, radiolabeling and evaluation of a new positively charged 99mTc-labeled fatty acid derivative for myocardial imaging
  76. Preparation and preliminary bioevaluation of 99mTc(CO)3-11β-progesterone derivative prepared via click chemistry route
  77. Preparation of177Lu-Labeled Oxine in Lipiodol as a Possible Agent for Therapy of Hepatocellular Carcinoma: A Preliminary Animal Study
  78. A novel 177Lu-labeled porphyrin for possible use in targeted tumor therapy
  79. Evaluation of new positively charged 11- and 12-carbon 99mTc-labeled fatty acid derivatives for myocardial imaging
  80. Biologic Evaluation of a Novel188Re-Labeled Porphyrin in Mice Tumor Model
  81. Synthesis, characterization and biological activity of99mTc-labeled piperidine analogues targeting sigma receptors
  82. 170Tm-EDTMP: a potential cost-effective alternative to 89SrCl2 for bone pain palliation
  83. Bioevaluation of 90Y-labeled particles in animal model of arthritis
  84. Preparation of 166Ho-oxine-lipiodol and its preliminary bioevaluation for the potential application in therapy of liver cancer
  85. 166Ho-Labeled Hydroxyapatite Particles: A Possible Agent for Liver Cancer Therapy
  86. Preparation andIn-VivoEvaluation of188Re(CO)3-Colchicine Complex for Use as Tumor-Targeting Agent
  87. Comparative studies of 177Lu–EDTMP and 177Lu–DOTMP as potential agents for palliative radiotherapy of bone metastasis
  88. Synthesis and bio-evaluation of a new fatty acid derivative for myocardial imaging
  89. Bioevaluation studies of 32P incorporated mould brachytherapy sources for potential application in treatment of superficial tumors
  90. Preparation and preliminary studies on 177Lu-labeled hydroxyapatite particles for possible use in the therapy of liver cancer
  91. 177Lu-EDTMP: A Viable Bone Pain Palliative in Skeletal Metastasis
  92. Synthesis of99mTc-Nitrido Heterocomplex of Piperidine andIn VitroandIn VivoEvaluation of Its Affinity for Sigma Receptors
  93. 177Lu-DOTMP: A viable agent for palliative radiotherapy of painful bone metastasis
  94. Preparation and biological studies of 125I-DOTA-TATE
  95. Comparative evaluation of heating ability and biocompatibility of different ferrite-based magnetic fluids for hyperthermia application
  96. Preparation and preliminary biological evaluation of 177Lu-labelled hydroxyapatite as a promising agent for radiation synovectomy of small joints
  97. 175Yb-labeled hydroxyapatite: a potential agent for use in radiation synovectomy of small joints
  98. Preparation and preliminary biological evaluation of a 177Lu labeled nitroimidazole derivative for possible use in targeted tumor therapy
  99. Evaluation of 90Y phosphate particles as a possible radiation synoviorthesis agent
  100. Preparation and biological evaluation of 153Sm-DOTMP as a potential agent for bone pain palliation